Disease modifying drugs may reduce risk of secondary progressive MS

21 January 2019

Source MS Trust:  People with relapsing remitting MS starting early treatment with a disease modifying drug have a lower risk of developing secondary progressive MS, according to a study of medical records.

People with relapsing remitting MS often find that, over time, their MS changes so that they have fewer or no relapses while, at the same time, their disability is increasing. This is called secondary progressive MS (SPMS). The change between relapsing remitting and secondary progressive MS is not a sudden switch but a gradual process.  Read on.

Blog categories: